Hims & Hers Health approaches its August 10 earnings call following a Q1 2026 report that showed modest 4% revenue growth to $608 million alongside a 9% subscriber increase to 2.6 million, driven by international expansion through acquisitions like ZAVA and Livewell. Management raised full-year 2026 revenue guidance to $2.8–3.0 billion while lowering adjusted EBITDA targets, reflecting margin pressure from the strategic pivot toward branded GLP-1 weight-loss medications and reduced compounded offerings in the U.S. Traders are monitoring commentary on GLP-1 adoption trends, average revenue per subscriber, domestic versus international mix, and the path back to profitability, with Q2 guidance of $680–700 million revenue serving as a key near-term benchmark amid ongoing platform investments in telehealth and specialty treatments.